SCHEMBL20346348

SCHEMBL20346348

CCOC(=O)Cc1ccc(C)c(C#N)c1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
NLRP3 Q96P20 1/20 0.43
CYP4Z1 Q86W10 1/20 0.43
L3MBTL1 Q9Y468 6/20 0.42
RAB9A P51151 5/20 0.42
SMN1; SMN2 Q16637 4/20 0.42
NPC1 O15118 4/20 0.42
NFKB1 P19838 2/20 0.42
NFKB2 Q00653 2/20 0.42
RELA Q04206 2/20 0.42
PKM P14618 1/20 0.42
MAPT P10636 6/20 0.42
KDM4E B2RXH2 3/20 0.41
CYP2C9 P11712 1/20 0.41
ALDH1A1 P00352 3/20 0.41
HPGD P15428 2/20 0.41
LMNA P02545 1/20 0.41
KMT2A Q03164 1/20 0.41
TSHR P16473 2/20 0.41
HSD17B10 Q99714 2/20 0.41
CASP1 P29466 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20045089 0.86 GAA (0.49) RAB9ASMN1; SMN2NPC1NFKB1NFKB2
SCHEMBL20772557 0.85 NLRP3 (0.41) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL12985044 0.85 MAPT (0.42) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL20349602 0.84 ALDH1A1 (0.48) SMN1; SMN2PKMKDM4EALDH1A1KMT2A
SCHEMBL23832225 0.82 MAPT (0.45) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL30154437 0.82 MAPT (0.45) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL5357828 0.82 DAO (0.43) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL286389 0.81 AR (0.45) SMN1; SMN2NFKB1PKMKDM4EALDH1A1
SCHEMBL29268084 0.81 SMN1; SMN2 (0.40) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2
SCHEMBL13492095 0.80 MEN1 (0.49) NLRP3CYP4Z1L3MBTL1RAB9ASMN1; SMN2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20180186721-A1 OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS THE GOVERNORS OF THE UNIVERSITY OF ALBERTA (CA) 2018-07-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180186721-A1 OXIDATIVE COUPLING OF ARYL BORON REAGENTS WITH SP3-CARBON NUCLEOPHILES, AND AMBIENT DECARBOXYLATIVE ARYLATION OF MALONATE HALF-ESTERS VIA OXIDATIVE CATALYSIS SOD1, AOC3, CBR3 NLRP3 3439/4885CYP4Z1 733/4885L3MBTL1 2188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.